Trial Setback For Gilead Sciences: Shuts Late-Stage Magrolimab/Azacitidine Combo Study In Type Of Blood Cancer
Portfolio Pulse from Vandana Singh
Gilead Sciences Inc has decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility based on a planned analysis. The study evaluated the combination of magrolimab plus azacitidine as first-line treatments for higher-risk MDS. The FDA had previously placed a partial clinical hold on the study due to suspected unexpected serious adverse reactions, but lifted the hold in April. Gilead is working on next steps for patients enrolled in the study.

July 24, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Gilead Sciences' decision to discontinue the Phase 3 ENHANCE study could negatively impact investor confidence and the company's stock price in the short term.
The discontinuation of a late-stage study is generally seen as a negative event for a pharmaceutical company, as it indicates a setback in the development of a potential new treatment. This could lead to a decrease in investor confidence and a potential drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100